THE MPACT STUDY INCLUDED
PATIENTS TYPICALLY SEEN IN REAL-WORLD PRACTICE1,2

ABRAXANE + gemcitabine vs gemcitabine study design for metastatic pancreatic cancer ABRAXANE + gemcitabine vs gemcitabine study design for metastatic pancreatic cancer
The MPACT Study for ARBAXANE + gemcitabine vs. gemcitabine included patients with a broad range of performance status (KPS 70-100) The MPACT Study for ARBAXANE + gemcitabine vs. gemcitabine included patients with a broad range of performance status (KPS 70-100)
There was no upper age limit in the Metastatic Pancreatic Cancer Trial (Age Range: 27-86) There was no upper age limit in the Metastatic Pancreatic Cancer Trial (Age Range: 27-86)
The MPACT Study was conducted in real-world treatment setting The MPACT Study was conducted in real-world treatment setting
Tumor burden1
  • 46% with ≥3 metastatic sites
  • 85% with liver metastases
  • KPS=Karnofsky Performance Status Scale; MPACT=Metastatic Pancreatic Adenocarcinoma Clinical Trial; PS=performance status.
  • Conversion: KPS to ECOG PS

    UNDERSTANDING THE RELATION BETWEEN
    PERFORMANCE STATUS MEASUREMENTS3-5
    UNDERSTANDING THE RELATION BETWEEN PERFORMANCE STATUS MEASUREMENTS3-5

    Conversion of Karnofsky Performance Status (KPS) to Eastern Cooperative Oncology Group Performance Status (ECOG PS) Eastern Cooperative Oncology Group Performance Status (ECOG PS)
    Eastern Cooperative Oncology Group Performance Status (ECOG PS)

    This proposed conversion scale was constructed empirically from a sample of patients (n=1385) with advanced cancer, including different tumor types. Both KPS and ECOG PS were determined by 7 physicians for each patient. This conversion scale had the highest rate of agreement (75%) observed among all possible scales.5

    CLOSE THE TAB
  • Patients Were Well Balanced Between Treatment Arms

    PATIENTS WERE WELL BALANCED
    BETWEEN TREATMENT ARMS1

    Patient characteristics of the MPACT Study: ABRAXANE + gemcitabine vs gemcitabine Patient characteristics of the MPACT Study: ABRAXANE + gemcitabine vs gemcitabine
    CLOSE THE TAB
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL